SITE009-0036

SITE009 (AUS) › SITE009-0036

SITE009-0036

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2025-10-17

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-27 (study day 315); relationship: NOT RELATED

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-11 (study day 237); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-13 (study day 25); relationship: NOT RELATED

moderate assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-04-27 (study day 9); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.